These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15464314)

  • 1. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
    Serruys PW; Ormiston JA; Sianos G; Sousa JE; Grube E; den Heijer P; de Feyter P; Buszman P; Schömig A; Marco J; Polonski L; Thuesen L; Zeiher AM; Bett JH; Suttorp MJ; Glogar HD; Pitney M; Wilkins GT; Whitbourn R; Veldhof S; Miquel K; Johnson R; Coleman L; Virmani R;
    J Am Coll Cardiol; 2004 Oct; 44(7):1363-7. PubMed ID: 15464314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
    Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
    Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents.
    Roy P; Steinberg DH; Sushinsky SJ; Okabe T; Pinto Slottow TL; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Weissman NJ; Lindsay J; Waksman R
    Eur Heart J; 2008 Aug; 29(15):1851-7. PubMed ID: 18550555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Mahaffey KW; Cutlip DE; Fitzgerald PJ; Sood P; Su X; Lansky AJ;
    JAMA; 2008 Apr; 299(16):1903-13. PubMed ID: 18430909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES).
    Serruys PW; Sianos G; Abizaid A; Aoki J; den Heijer P; Bonnier H; Smits P; McClean D; Verheye S; Belardi J; Condado J; Pieper M; Gambone L; Bressers M; Symons J; Sousa E; Litvack F
    J Am Coll Cardiol; 2005 Jul; 46(2):253-60. PubMed ID: 16022951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Kim HS; Ko JK; Park JH; Lee JH; Choi SW; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Park SJ
    J Am Coll Cardiol; 2008 Mar; 51(12):1181-7. PubMed ID: 18355656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
    Grube E; Sonoda S; Ikeno F; Honda Y; Kar S; Chan C; Gerckens U; Lansky AJ; Fitzgerald PJ
    Circulation; 2004 May; 109(18):2168-71. PubMed ID: 15123533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
    Waksman R; Ajani AE; Pichard AD; Torguson R; Pinnow E; Canos D; Satler LF; Kent KM; Kuchulakanti P; Pappas C; Gambone L; Weissman N; Abbott MC; Lindsay J;
    J Am Coll Cardiol; 2004 Oct; 44(7):1386-92. PubMed ID: 15464317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-eluting stent implantation and beta-irradiation for the treatment of in-stent restenotic lesions: comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound.
    Schiele TM; König A; Rieber J; Erhard I; Leibig M; Theisen K; Siebert U; Klauss V
    Am Heart J; 2005 Aug; 150(2):351-7. PubMed ID: 16086942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION).
    Chechi T; Vittori G; Biondi Zoccai GG; Vecchio S; Falchetti E; Spaziani G; Baldereschi G; Giglioli C; Valente S; Margheri M
    J Interv Cardiol; 2007 Aug; 20(4):282-91. PubMed ID: 17680858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials.
    Weissman NJ; Ellis SG; Grube E; Dawkins KD; Greenberg JD; Mann T; Cannon LA; Cambier PA; Fernandez S; Mintz GS; Mandinov L; Koglin J; Stone GW
    Eur Heart J; 2007 Jul; 28(13):1574-82. PubMed ID: 17540849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of intravascular ultrasound to predict outcomes in short-length lesions treated with drug-eluting stents.
    Yoon YW; Shin S; Kim BK; Kim JS; Shin DH; Ko YG; Choi D; Jeon DW; Kwon H; Jang Y; Hong MK;
    Am J Cardiol; 2013 Sep; 112(5):642-6. PubMed ID: 23711810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.